🧬 Aging Wiki

age-related-cataract

Properties1
aliasessenile cataract, age-related lens opacity, ARC

16 min read

⚠️ Partial source-verification pass completed 2026-08-18. Zhao 2015 was checked against the version-of-record main article, but its Online Methods, Extended Data, and Source Data were unavailable; the full post-hoc EDTA article (Kuboi 2024) was also unavailable. Claims that depend on inaccessible material are excluded or tagged #gap/no-fulltext-access. Verification remains incomplete.

Age-related cataract

TL;DR

An age-related cataract is a progressive loss of lens transparency caused principally by damage, misfolding, aggregation, and insolubilization of exceptionally long-lived lens crystallins. Oxidation, impaired glutathione access to the lens nucleus, deamidation, isomerization, glycation, and declining alpha-crystallin chaperone capacity converge on this proteostasis failure. Age is the dominant risk factor; smoking, diabetes, cumulative ultraviolet-B exposure, and prolonged corticosteroid exposure are important modifiable or iatrogenic associations. Cataract extraction with intraocular-lens implantation is the only established way to remove a cataract. Drug or eye-drop approaches remain investigational: early lanosterol results have not reproduced consistently, small EDTA data are exploratory, and an eight-participant US study of ZOC2017217 was active but no longer recruiting and had no posted results as of this literature check.

This page concerns common acquired age-related cataract, not congenital, traumatic, radiation-induced, inflammatory, or drug-induced cataracts as primary diagnoses. Age-related cataracts can nevertheless be accelerated by those exposures or conditions. ICD-10-CM H25 and ICD-11 9B10.0 identify the age-related category.1

Clinical phenotype

The transparent lens focuses light by maintaining a precisely ordered, highly concentrated protein environment. Cataract is diagnosed when lens opacity becomes visible on examination; it becomes clinically important when it degrades a person’s function. Typical complaints include blurred or hazy vision, glare and halos, reduced contrast or night vision, fading or yellowing of colors, and frequent refractive changes.2

The major anatomical patterns overlap.3

PatternTypical location and appearanceCommon functional consequence
Nuclear scleroticCentral lens nucleus; progressive hardening, yellowing, then brunescenceMyopic shift, reduced distance vision, color and contrast loss
CorticalRadial spoke-like opacities in the outer lens cortexGlare and variable acuity as spokes enter the visual axis
Posterior subcapsularPlaque-like opacity immediately anterior to the posterior capsuleDisproportionate glare and near-vision impairment; often faster functional progression

Subtype matters mechanistically and epidemiologically. A risk association for nuclear cataract cannot automatically be generalized to cortical or posterior-subcapsular cataract. Clinical grading systems, surgical thresholds, and whether prior cataract surgery is counted as disease also materially change prevalence estimates. A meta-analysis included 45 population studies with 161,947 participants across broad age ranges; among studies reporting age-60-and-older strata, pooled prevalence was 54.4%, with extreme heterogeneity across regions and grading definitions.4

Why the aging lens loses transparency

Lifelong crystallins create an unusual proteostasis problem

Mature fiber cells in the lens nucleus lose their nuclei and other organelles and cannot replace damaged proteins. Radiocarbon dating found that nuclear lens crystallins are laid down early in life and undergo essentially no turnover thereafter.5 The same protein molecules must therefore remain soluble and correctly packed for decades.

Alpha-, beta-, and gamma-crystallins supply both refractive structure and, for alpha-crystallins, molecular-chaperone activity. With age:

  • spontaneous deamidation, racemization/isomerization, truncation, oxidation, and glycation accumulate;
  • alpha-crystallin becomes increasingly incorporated into high-molecular-weight and water-insoluble material, exhausting soluble chaperone reserve;
  • altered crystallins expose hydrophobic surfaces, cross-link, and form aggregates large enough to scatter visible light.

Mass-spectrometry studies of human lenses show extensive age- and cataract-associated post-translational modification, with deamidation enriched in water-insoluble fractions.6 In human lenses spanning ages 10—76 years, aspartate isomerization was greater in more aggregated fractions, while the chaperone activity of soluble alpha-crystallin declined with age; the high-molecular-weight fraction had little remaining chaperone activity. The study did not establish a monotonic age relationship for isomerization itself.7 These findings make loss-of-proteostasis the strongest proximal Hallmark mapping for nuclear and cortical cataract. Posterior-subcapsular cataract may also involve a distinct lens-epithelial senescence and inflammatory route described below.

Oxidative and redox failure

The lens depends heavily on reduced glutathione and related antioxidant systems. Ex-vivo radiotracer experiments found that little newly synthesized glutathione reached the center of normal human lenses from donors older than 30 years, supporting an age-dependent barrier between the metabolically active cortex and nucleus.8 Oxidation then promotes intra- and intermolecular disulfide exchange. Redox proteomics found conserved cysteine oxidation and disulfide formation in enzymes and cytoskeletal proteins in cataractous human lenses and glutathione-depleted mouse lenses, complementing prior crystallin-disulfide work.9

This is not simply a claim that any antioxidant will reverse opacity. Once covalent modification, misfolding, and large aggregates are established, restoring bulk antioxidant concentration may be insufficient. A 2026 biochemical study found that engineered cysteine-depleted human gamma-D-crystallin variants aggregated from C-terminal disulfide-bridged dimers after partial destabilization, while the endogenous osmolyte myo-inositol suppressed aggregation; this is a mechanistic lead, not evidence for an eye-drop treatment.10

Glycation and other age-dependent chemical damage

Long residence time also exposes crystallins to nonenzymatic glycation. Human cataract-lens studies have detected advanced glycation end products, including the fluorescent lysine-arginine cross-link pentosidine, and found more glycation and non-tryptophan fluorescence in crystallins and high-molecular-weight aggregates with age or diabetes.1112 These associations support glycation as one contributor to protein aggregation; they do not make age-related cataract a single-AGE disease.

Risk factors and causal confidence

FactorEvidence and interpretation
Increasing ageDominant determinant because molecular damage accumulates in proteins that are not replaced.
[[exposures/smokingSmoking]]
[[type-2-diabetesDiabetes]]
Ultraviolet-B exposureIn 838 Chesapeake Bay watermen, doubling cumulative UV-B exposure was associated with cortical cataract (OR 1.60) but not nuclear cataract.13 This subtype specificity supports [[interventions/lifestyle/uv-protection
CorticosteroidsProlonged systemic treatment and high-dose inhaled exposure are associated with cataract. A UK case-control study of 15,479 cataract cases found adjusted dose- and duration-response associations for inhaled corticosteroids but did not record cataract subtype.14 Prescribed steroids should not be stopped without clinical guidance.
Ocular and inherited contextPrior eye injury or surgery, radiation exposure, and family history can shift risk or onset; these factors are not interchangeable with ordinary chronological aging.2

Most risk estimates are observational. A 2023 Mendelian-randomization analysis supported genetically proxied myopia and primary open-angle glaucoma as cataract risks but did not support several other epidemiologic associations, including diabetes and smoking, in its tested instruments.15 That null genetic result does not prove the clinical associations are spurious: lifelong germline instruments may poorly represent exposure dose, disease duration, treatment, or subtype-specific effects. It does mean that association, mechanism, and preventability should be kept separate.

Diagnosis and natural history

A comprehensive dilated eye examination combines visual-acuity and functional history with assessment of lens opacity.2 Early cataract may be managed with an updated refraction, brighter task lighting, and glare control. Progression is variable, and surgery is generally considered when vision loss interferes with everyday activities rather than when an opacity reaches a fixed grade.16

Management

Established treatment: lens extraction and intraocular-lens implantation

Cataract surgery removes the cloudy natural lens and replaces its focusing power with an artificial intraocular lens. Modern surgery is usually performed through a small incision with phacoemulsification, although technique depends on anatomy and setting. It is the only established treatment that removes the cataract; the US National Eye Institute reports improved vision in about 9 of 10 operated patients.16

Surgery is highly effective but not biologically trivial. Important risks include swelling, bleeding, infection, unusual eye-pressure changes, retinal detachment, vision loss or double vision, and later posterior-capsule opacification.16 Ocular comorbidity can limit the attainable vision. Claims that an investigational drop “ends cataract surgery” are therefore premature unless a controlled human trial demonstrates durable improvements in both lens opacity and patient-relevant visual function with acceptable safety.

Risk reduction is not cataract reversal

Smoking cessation and protection from cumulative ultraviolet exposure are reasonable risk-reduction measures; diabetes and corticosteroid exposure should be managed with the relevant clinician. None guarantees prevention, and the intervention should match the exposure rather than treating every cataract as an antioxidant deficiency. In the 4,629-participant AREDS randomized trial, high-dose vitamins C and E plus beta-carotene did not reduce cataract development or progression over a mean 6.3 years (OR 0.97; P=0.55).17 Commercial N-acetylcarnosine cataract drops likewise lack a reliable efficacy base: a Cochrane review found no study meeting its inclusion criteria, while two potentially eligible small studies could not be classified from the available information.18

Castor-oil studies sometimes cited in eye-drop discussions do not test cataract reversal. The located clinical trials evaluated periocular castor oil for blepharitis or low-concentration castor-oil drops for meibomian-gland dysfunction and tear-film endpoints; neither measured crystalline-lens opacity.19

Investigational non-surgical approaches

ApproachCurrent evidenceInterpretation
lanosterol and related oxysterolsThe original [[studies/zhao-2015-lanosterol-cataractsZhao 2015]] study reported reduced crystallin aggregation and improved transparency or cataract severity in preclinical systems.20 Extracted human cataract nuclei in [[studies/shanmugam-2015-lanosterol-human-cataract-nuclei
Lens-targeted LSS mRNAIn separate normal-rat experiments, [[studies/song-2025-lss-mrna-cataract-ratsSong 2025]] found increased lens hLSS and lanosterol 24 hours after intracameral lipid-nanoparticle mRNA delivery. Efficacy experiments suppressed a selenite cataract when dosing began before induction and reduced an established galactose opacity, but did not measure hLSS/lanosterol in those disease cohorts.21
Alpha-crystallin pharmacological chaperonesA small-molecule screen identified compound 29, which stabilized alpha-crystallins and improved transparency or soluble-protein measures in hereditary/aged mouse and ex-vivo human systems.22Mechanistic and preclinical evidence only; no demonstrated clinical efficacy. Delivery and off-target safety remain unresolved.
EDTA ophthalmic solution[[studies/kuboi-2024-edta-cataract-subgroupKuboi 2024]] reported exploratory contrast-sensitivity and lens-density signals in a post-hoc 41-eye subgroup (21 EDTA; 20 placebo) of a phase 1/2 trial.23
zoc2017217 ophthalmic solutionNCT07395986 is a randomized, quadruple-masked, placebo-controlled US phase 2 pilot of 0.4% ZOC2017217 twice daily for 24 weeks. The structured registry record changed to ACTIVE_NOT_RECRUITING with 8 actual participants on 2026-08-11; the brief summary still retains the earlier plan for approximately 40, and no results were posted as of 2026-08-18.24A registered, incompletely accrued trial establishes that the hypothesis is being tested, not that the drug works or will replace surgery. Primary completion is estimated for February 2027.

Protein repair and deglycation strategies such as fn3k provide additional multi-species ex-vivo and mouse mechanistic leads, but not clinical evidence of cataract reversal.25

Hallmark mapping

  • loss-of-proteostasis — primary/proximal: crystallin damage, chaperone depletion, aggregation, and insolubilization directly generate light scatter.
  • cellular-senescence — subtype-specific/supporting: a 2026 study of human age-related posterior-subcapsular cataract found senescence/SASP, IL-17A/NF-kappa-B, and epithelial-to-mesenchymal-transition signatures relative to age-related nuclear-cataract and clear-lens specimens. IL-17A blockade or senolysis attenuated related phenotypes in cultured or ex-vivo lens epithelial cells, but the small discovery and validation sets and absence of a human intervention trial preclude generalizing this mechanism to all cataracts.26
  • Oxidative and glycation damage — upstream amplifiers: redox failure and AGE cross-links accelerate the proteostasis collapse but do not define every subtype.

Current research frontier and gaps

A 2025 preprint reported single-nucleus RNA sequencing of 230,838 lens epithelial-cell nuclei from anterior capsules of 554 cataract-surgery patients across mild, severe cortical, and severe nuclear groups, and proposed cellular-state and neuro-lens signaling changes.27 Because all sequenced samples came from people already undergoing cataract surgery, and the work was not peer reviewed as of this check, it is an observational hypothesis-generating map rather than proof that any identified cell state initiates cataract.

Highest-priority gaps:

  1. Reversal versus prevention: distinguish dissolution of an established, functionally significant opacity from slowing early progression.
  2. Subtype and stage: prospectively stratify nuclear, cortical, and posterior-subcapsular cataracts and define when a damaged lens is no longer pharmacologically recoverable.
  3. Delivery: measure drug concentration and target engagement in the human lens nucleus, not only cornea, aqueous humor, or cultured crystallins.
  4. Patient-relevant endpoints: pair standardized lens densitometry/grading with best-corrected acuity, contrast sensitivity, glare disability, quality of life, and time to surgery.
  5. Replication: confirm promising molecular-chaperone, redox, chelation, and gene-delivery results across independent laboratories before large efficacy trials.
  6. Safety horizon: chronic topical or intraocular therapy must be compared with the high success rate and finite treatment course of surgery.

Footnotes

Footnotes

  1. WHO ICD-10 browser, H25, “Senile cataract” (ICD-10); WHO ICD-11 MMS, 9B10.0, “Age-related cataract” (ICD-11). Canonical classification sources; terminology differs between revisions. ↩

  2. US National Eye Institute. Cataracts. Canonical clinical overview; updated 2025-11-26; accessed 2026-08-18. ↩ ↩2 ↩3

  3. American Academy of Ophthalmology EyeWiki. Cataract. Authoritative clinical description of nuclear-sclerotic, cortical, and posterior-subcapsular patterns; accessed 2026-08-18. ↩

  4. doi:10.1038/s41433-020-0806-3 · Hashemi H et al. · systematic review/meta-analysis · 45 studies, total n=161,947 across included age ranges; 40 studies reported age-60+ strata · pooled age-60+ prevalence 54.38% (95% CI 47.57—61.18) · I² >97% · Eye 2020 · PMID:32055021 · PMCID:PMC7376226. ↩

  5. doi:10.1371/journal.pone.0001529 · Lynnerup N et al. · radiocarbon dating of nuclear crystallins from 13 human lenses · most crystallin formation occurred around birth, with only a small decreasing component of later synthesis and no remodeling of established nuclear proteins · PLoS One 2008 · PMID:18231610 · PMCID:PMC2211393. ↩

  6. doi:10.1021/pr050473a · Wilmarth PA et al. · mass-spectrometric comparison of young, aged, and cataractous human lenses · 491 putative modification sites passed initial filters, of which 155 aged-lens crystallin modifications met the study’s in-vivo filters; deamidation was enriched in water-insoluble fractions · J Proteome Res 2006 · PMID:17022627 · PMCID:PMC2536618. ↩

  7. doi:10.1016/j.bbapap.2020.140446 · Fujii N et al. · human lenses ages 10—76 · size-exclusion chromatography, chaperone assay, and LC-MS analysis · isomerized aspartate was enriched with aggregation state, while soluble alpha-crystallin chaperone activity declined with age; the isomerization-age relationship remained unclear · Biochim Biophys Acta Proteins Proteom 2020 · PMID:32442520. ↩

  8. doi:10.1006/exer.1998.0549 · Sweeney MHJ, Truscott RJW · ex-vivo normal human lenses with [35S]cysteine metabolic-radiotracer experiments · supported an age-dependent impediment to glutathione movement into the lens nucleus · Exp Eye Res 1998 · PMID:9878221. ↩

  9. doi:10.1111/acel.12548 · Wang Z et al. · redox proteomics of noncrystallin proteins in human cataract, glutathione-depleted LEGSKO mouse cataract, and in-vitro oxidation · 17 proteins were shared across all three disulfidomes · Aging Cell 2017 · PMID:28177569 · PMCID:PMC5334568. ↩

  10. doi:10.1016/j.jbc.2026.113241 · Pu Y et al. · engineered cysteine-depleted recombinant human gamma-D-crystallin variants in vitro · C-terminal disulfide-bridged dimers aggregated after mild destabilization; myo-inositol strongly suppressed aggregation · mechanistic only · J Biol Chem 2026 · PMID:42264090. ↩

  11. doi:10.2337/diab.40.8.1010 · Lyons TJ et al. · cataractous lens crystallins from 29 diabetic and 24 nondiabetic older patients · pentosidine and fructoselysine were higher in diabetic lenses · Diabetes 1991 · PMID:1907246. ↩

  12. doi:10.1016/0014-4835(92)90046-U · Swamy MS, Abraham A, Abraham EC · soluble and insoluble crystallin fractions from human lenses ages 16—85 · glycation and non-tryptophan fluorescence increased with age and were greatest in high-molecular-weight aggregates · Exp Eye Res 1992 · PMID:1521566. ↩

  13. doi:10.1056/NEJM198812013192201 · Taylor HR et al. · cross-sectional study of 838 watermen · reconstructed cumulative UV-B exposure associated with cortical, not nuclear, cataract · N Engl J Med 1988 · PMID:3185661. ↩

  14. doi:10.1136/bjo.87.10.1247 · Smeeth L et al. · UK population case-control study · 15,479 cataract cases with matched controls · adjusted dose- and duration-response associations for inhaled corticosteroids; cataract subtype was unavailable · Br J Ophthalmol 2003 · PMID:14507760 · PMCID:PMC1920769. ↩

  15. doi:10.1167/iovs.64.10.19 · Jiang Z et al. · two-sample Mendelian randomization using cataract and exposure GWAS datasets · supported myopia and primary open-angle glaucoma signals but not several observational risk factors · genetic-instrument assumptions and phenotype definitions limit interpretation · Invest Ophthalmol Vis Sci 2023 · PMID:37459064 · PMCID:PMC10362921. ↩

  16. US National Eye Institute. Cataract Surgery. Canonical patient-care source; updated 2024-12-05; accessed 2026-08-18. ↩ ↩2 ↩3

  17. doi:10.1001/archopht.119.10.1439 · Age-Related Eye Disease Study Research Group · randomized placebo-controlled trial · n=4,629, ages 55—80, mean follow-up 6.3 years · high-dose antioxidant formulation did not reduce cataract development/progression · Arch Ophthalmol 2001 · PMID:11594943 · PMCID:PMC1472812. ↩

  18. doi:10.1002/14651858.CD009493.pub2 · Dubois VD-P, Bastawrous A · Cochrane systematic review of N-acetylcarnosine for age-related cataract · no study met inclusion criteria; two studies totaling 114 participants awaited classification because required information was unavailable · Cochrane Database Syst Rev 2017 · PMID:28245346 · PMCID:PMC6464029. ↩

  19. doi:10.1016/j.jtos.2020.05.007 · Muntz A et al. · 26-participant randomized paired-eye trial of periocular castor oil for blepharitis and ocular-surface/tear-film outcomes · Ocul Surf 2021 · PMID:32422285. doi:10.1016/S0161-6420(02)01262-9 · Goto E et al. · randomized double-masked crossover trial, 20 patients/40 eyes, of castor-oil drops for noninflamed obstructive meibomian-gland dysfunction · Ophthalmology 2002 · PMID:12414410. Neither study evaluated lens opacity. ↩

  20. doi:10.1038/nature14650 · Zhao L et al. · preclinical biochemical, rabbit-lens, and canine cataract experiments · original lanosterol-positive report · Nature 2015 · PMID:26200341. Version-of-record main article checked; Online Methods, Extended Data, and Source Data were unavailable, so supplement-only treatment details are excluded here. ↩

  21. doi:10.1038/s41467-025-63553-5 · Song R et al. · intracameral pB-UC18 lipid-nanoparticle LSS mRNA in rats · selenite dosing started one day before induction; a separate established galactose cataract was treated afterward · hLSS and lanosterol were measured at 24 hours in separate normal-rat experiments, not the efficacy cohorts · within-lens expression was strongest in epithelium/cortex, with additional ocular-tissue signal · Nat Commun 2025 · PMID:41006301 · PMCID:PMC12474983. ↩

  22. doi:10.1126/science.aac9145 · Makley LN et al. · biochemical screen plus hereditary/aged mouse and ex-vivo human-lens experiments · compound 29 stabilized alpha-crystallins and improved preclinical transparency/protein-solubility measures · no clinical trial · Science 2015 · PMID:26542570 · PMCID:PMC4725592. ↩

  23. doi:10.1016/j.ajo.2024.07.038 · Kuboi T et al. · post-hoc subgroup of randomized double-masked phase 1/2 trial · 41 eyes (21 EDTA; 20 placebo); responder endpoint 66.7% versus 35.0% at day 120 (P=0.043), with lens density assessed in a smaller imaging subset · Am J Ophthalmol 2024 · PMID:39098755. Full article unavailable for this verification pass; claim limited to the primary abstract/publisher record. ↩

  24. NCT07395986 · randomized, quadruple-masked phase 2 pilot · 0.4% ZOC2017217 ophthalmic solution versus placebo · 24-week treatment · status ACTIVE_NOT_RECRUITING, 8 actual participants, estimated primary/completion February 2027, no posted results · record update posted 2026-08-11. The brief summary still says approximately 40 subjects, reflecting a registry-field inconsistency/version remnant. ↩

  25. doi:10.3390/ijms22083841 · De Bruyne S et al. · FN3K treatment in equine and porcine lens tissue, mouse intraocular delivery, and human lens suspensions · reductions in AGE-related autofluorescence and color endpoints; no human clinical trial · Int J Mol Sci 2021 · PMID:33917258 · PMCID:PMC8068021. ↩

  26. doi:10.1111/acel.70456 · Ni Y et al. · clinically stratified human age-related posterior-subcapsular cataract, age-related nuclear-cataract, and clear-lens specimens plus cultured and ex-vivo lens-epithelial-cell experiments · RNA sequencing n=3/group; validation assays generally n=4—6/group · senescence/SASP, IL-17A/NF-kappa-B, and epithelial-to-mesenchymal-transition signals were enriched in posterior-subcapsular cataract; IL-17A blockade or senolysis attenuated related experimental phenotypes · no human treatment trial · Aging Cell 2026 · PMID:41876404 · PMCID:PMC13092507. ↩

  27. doi:10.21203/rs.3.rs-7580840/v1 · Yu Y, Tang Q, Tong Z et al. · single-nucleus RNA sequencing of 230,838 lens epithelial-cell nuclei from anterior capsules of 554 cataract-surgery patients · cross-sectional mild/severe-cortical/severe-nuclear groups · Research Square preprint posted 2025-09-22; not peer reviewed as of 2026-08-18. ↩

Graph View

Backlinks